Top

Published in:

01-10-2018 | Literatur kommentiert

Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology

Authors: Dr.med. Christoph Süß, Prof. Dr. med. Oliver Kölbl

Published in: Strahlentherapie und Onkologie | Issue 10/2018

Auszug

In der hier zu kommentierenden Arbeit wird die Behandlung des Pleuramesothelioms (MPM) von einer interdisziplinären Expertenkommission der American Society of Clinical Oncology (ASCO) im Sinn einer Praxisleitlinie (für die behandelnden Ärzte) beleuchtet. Ziel der Arbeit war es, praktizierenden Ärzten eine evidenzbasierte interdisziplinäre Empfehlung zum Management und zur Behandlung des MPM zur Verfügung zu stellen. …

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v31–v39. https://doi.org/10.1093/annonc/mdv199 CrossRefPubMed

Bece A, Tin MM, Darren M, Lin R, McLean J, McCaughan B (2015) Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: toxicity and outcomes at an Australian institution. J Med Imaging Radiat Oncol 59(3):355–362. https://doi.org/10.1111/1754-9485.12291 CrossRefPubMed

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N et al (2016) Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol 17(8):1094–1104. https://doi.org/10.1016/S1470-2045(16)30095-X CrossRefPubMedPubMedCentral

Ettinger DS et al (2018) NCCN Guidelines Version 2.2018 Malignant Pleural Mesothelioma. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Zugegriffen: 03.05.2018

Froment M‑A, Frechette E, Dagnault A (2011) Prophylactic irradiation of intervention sites in malignant pleural mesothelioma. Radiother Oncol 101(2):307–310. https://doi.org/10.1016/j.radonc.2011.08.038 CrossRefPubMed

Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS et al (2013) Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238–245. https://doi.org/10.1097/JTO.0b013e31827740f0 CrossRefPubMedPubMedCentral

de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S (1999) Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 43(3):511–516CrossRef

Krayenbuehl J, Oertel S, Davis JB, Ciernik IF (2007) Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 69(5):1593–1599. https://doi.org/10.1016/j.ijrobp.2007.07.2370 CrossRefPubMed

Krayenbuehl J, Riesterer O, Graydon S, Dimmerling P, Kloeck S, Ciernik IF (2013) Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleuralpleuropneumonectomy. J Appl Clin Med Phys 14(4):4130. https://doi.org/10.1120/jacmp.v14i4.4130 CrossRefPubMed

10.

MacLeod N, Chalmers A, O’Rourke N, Moore K, Sheridan J, McMahon L et al (2015) Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. J Thorac Oncol 10(6):944–950. https://doi.org/10.1097/JTO.0000000000000499 CrossRefPubMed

11.

Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10–9. https://doi.org/10.1016/j.ijrobp.2009.07.1754 CrossRefPubMedPubMedCentral

12.

Mordant P, McRae K, Cho J, Keshavjee S, Waddell TK, Feld R, de Perrot M et al (2016) Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk? Eur J Cardiothorac Surg 50(3):433–438. https://doi.org/10.1093/ejcts/ezw074 CrossRefPubMed

13.

Pan HY, Jiang S, Sutton J, Liao Z, Chance WW, Frank SJ et al (2015) Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series. Pract Radiat Oncol 5(4):e345–e353. https://doi.org/10.1016/j.prro.2014.11.005 CrossRefPubMed

14.

de Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, Keshavjee S, Cho BCJ (2016) Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 151(2):468–473. https://doi.org/10.1016/j.jtcvs.2015.09.129 CrossRefPubMed

15.

Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS et al (2005) Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 80(6):1988–1992. https://doi.org/10.1016/j.athoracsur.2005.06.014 (discussion 1992–3)CrossRefPubMed

16.

Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ et al (2016) Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural Mesothelioma. J Clin Oncol 34(23):2761–2768. https://doi.org/10.1200/JCO.2016.67.2675 CrossRefPubMedPubMedCentral

17.

Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS et al (2012) Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 83(4):1278–1283. https://doi.org/10.1016/j.ijrobp.2011.09.027 CrossRefPubMedPubMedCentral

18.

Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122(4):788–795. https://doi.org/10.1067/mtc.2001.116560 CrossRefPubMed

19.

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35(3):479–495. https://doi.org/10.1183/09031936.00063109 CrossRefPubMed

20.

Scorsetti M, Bignardi M, Clivio A, Cozzi L, Fogliata A, Lattuada P et al (2010) Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study. Int J Radiat Oncol Biol Phys 77(3):942–949. https://doi.org/10.1016/j.ijrobp.2009.09.053 CrossRefPubMed

21.

Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Seyer S et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 10:267. https://doi.org/10.1186/s13014-015-0575-5 CrossRefPubMedPubMedCentral

Title: Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology
Authors: Dr.med. Christoph Süß
Prof. Dr. med. Oliver Kölbl
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 10/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1354-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology

Auszug

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 10/2018

Early versus late prophylactic cranial irradiation in patients with extensive small cell lung cancer

Hochrisiko-Endometriumkarzinom: Immer eine adjuvante Radiochemotherapie?

Complementary medicine in radiation oncology

Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math

Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients

Prognostic factors in stereotactic body radiotherapy of lung metastases